Go Pro
→ Wall Street is staring at the wrong AI trade (From The Oxford Club) (Ad)tc pixel Free GLUE Stock Alerts

Monte Rosa Therapeutics (GLUE) Competitors

Monte Rosa Therapeutics logo
$15.50 -0.34 (-2.15%)
Closing price 04:00 PM Eastern
Extended Trading
$15.86 +0.36 (+2.29%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

GLUE vs. CRSP, ACAD, DYN, CELC, and PBLS

Should you buy Monte Rosa Therapeutics stock or one of its competitors? Monte Rosa Therapeutics's main competitors and comparable companies include CRISPR Therapeutics (CRSP), ACADIA Pharmaceuticals (ACAD), Dyne Therapeutics (DYN), Celcuity (CELC), and Parabilis Medicines (PBLS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Monte Rosa Therapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings.

In the previous week, CRISPR Therapeutics had 2 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 8 mentions for CRISPR Therapeutics and 6 mentions for Monte Rosa Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.99 beat Monte Rosa Therapeutics' score of 0.06 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Monte Rosa Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CRISPR Therapeutics presently has a consensus price target of $68.06, suggesting a potential upside of 27.09%. Monte Rosa Therapeutics has a consensus price target of $28.50, suggesting a potential upside of 83.87%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.58
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

Monte Rosa Therapeutics has a net margin of -560.85% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Monte Rosa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-3,368.72% -24.39% -18.25%
Monte Rosa Therapeutics -560.85%-43.31%-27.59%

Monte Rosa Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$3.51M1,475.14-$581.60M-$4.76N/A
Monte Rosa Therapeutics$123.67M10.69-$38.63M-$1.76N/A

CRISPR Therapeutics has a beta of 1.74, meaning that its share price is 74% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

Summary

Monte Rosa Therapeutics beats CRISPR Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ACADIA Pharmaceuticals currently has a consensus target price of $33.69, indicating a potential upside of 19.31%. Monte Rosa Therapeutics has a consensus target price of $28.50, indicating a potential upside of 83.87%. Given Monte Rosa Therapeutics' higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ACADIA Pharmaceuticals
0 Sell rating(s)
3 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.82
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

ACADIA Pharmaceuticals has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 17 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 23 mentions for ACADIA Pharmaceuticals and 6 mentions for Monte Rosa Therapeutics. ACADIA Pharmaceuticals' average media sentiment score of 0.73 beat Monte Rosa Therapeutics' score of 0.06 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ACADIA Pharmaceuticals
9 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Monte Rosa Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

ACADIA Pharmaceuticals has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ACADIA Pharmaceuticals$1.14B4.27$391M$2.2212.72
Monte Rosa Therapeutics$123.67M10.69-$38.63M-$1.76N/A

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Monte Rosa Therapeutics' net margin of -560.85%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Monte Rosa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ACADIA Pharmaceuticals33.42% 9.03% 6.79%
Monte Rosa Therapeutics -560.85%-43.31%-27.59%

Summary

ACADIA Pharmaceuticals beats Monte Rosa Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Dyne Therapeutics presently has a consensus price target of $34.42, suggesting a potential upside of 33.92%. Monte Rosa Therapeutics has a consensus price target of $28.50, suggesting a potential upside of 83.87%. Given Monte Rosa Therapeutics' higher possible upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Dyne Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
1 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.87
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Monte Rosa Therapeutics had 3 more articles in the media than Dyne Therapeutics. MarketBeat recorded 6 mentions for Monte Rosa Therapeutics and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat Monte Rosa Therapeutics' score of 0.06 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Monte Rosa Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Monte Rosa Therapeutics has higher revenue and earnings than Dyne Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dyne TherapeuticsN/AN/A-$446.21M-$3.33N/A
Monte Rosa Therapeutics$123.67M10.69-$38.63M-$1.76N/A

Dyne Therapeutics has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

Dyne Therapeutics has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Dyne Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dyne TherapeuticsN/A -64.30% -50.33%
Monte Rosa Therapeutics -560.85%-43.31%-27.59%

Summary

Dyne Therapeutics and Monte Rosa Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Celcuity?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Monte Rosa Therapeutics currently has a consensus price target of $28.50, suggesting a potential upside of 83.87%. Celcuity has a consensus price target of $153.64, suggesting a potential upside of 67.00%. Given Monte Rosa Therapeutics' higher possible upside, equities research analysts plainly believe Monte Rosa Therapeutics is more favorable than Celcuity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Celcuity
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82

Celcuity has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Celcuity's return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics-560.85% -43.31% -27.59%
Celcuity N/A -244.61%-50.22%

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Celcuity had 14 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 20 mentions for Celcuity and 6 mentions for Monte Rosa Therapeutics. Celcuity's average media sentiment score of 0.84 beat Monte Rosa Therapeutics' score of 0.06 indicating that Celcuity is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monte Rosa Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Celcuity
7 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Positive

Monte Rosa Therapeutics has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$123.67M10.69-$38.63M-$1.76N/A
CelcuityN/AN/A-$177.04M-$4.30N/A

Monte Rosa Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market.

Summary

Monte Rosa Therapeutics beats Celcuity on 9 of the 15 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

Monte Rosa Therapeutics currently has a consensus target price of $28.50, indicating a potential upside of 83.87%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 12.40%. Given Monte Rosa Therapeutics' higher possible upside, equities analysts plainly believe Monte Rosa Therapeutics is more favorable than Parabilis Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Monte Rosa Therapeutics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67
Parabilis Medicines
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.00

Parabilis Medicines has lower revenue, but higher earnings than Monte Rosa Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Monte Rosa Therapeutics$123.67M10.69-$38.63M-$1.76N/A
Parabilis MedicinesN/AN/AN/AN/AN/A

Parabilis Medicines has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Parabilis Medicines' return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Monte Rosa Therapeutics-560.85% -43.31% -27.59%
Parabilis Medicines N/A N/A N/A

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Parabilis Medicines had 1 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 7 mentions for Parabilis Medicines and 6 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.06 beat Parabilis Medicines' score of -0.15 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Monte Rosa Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Parabilis Medicines
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Monte Rosa Therapeutics and Parabilis Medicines tied by winning 6 of the 12 factors compared between the two stocks.

Get Monte Rosa Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLUE vs. The Competition

Export
MetricMonte Rosa TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.32B$3.71B$6.97B$13.05B
Dividend YieldN/A3.76%2.58%10.72%
P/E Ratio-8.8110.68269.8625.30
Price / Sales10.691,293.47598.68101.54
Price / CashN/A103.0170.5350.75
Price / Book2.7117.4913.086.33
Net Income-$38.63M-$13.32M$3.45B$347.70M
7 Day Performance-2.39%1.77%1.14%1.08%
1 Month Performance-33.93%1.63%1.81%1.04%
1 Year Performance256.32%56.45%67.69%20.77%

Monte Rosa Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GLUE
Monte Rosa Therapeutics
2.8238 of 5 stars		$15.50
-2.1%		$28.50
+83.9%		+256.8%$1.32B$123.67MN/A90
CRSP
CRISPR Therapeutics
3.6184 of 5 stars		$53.13
+2.9%		$68.06
+28.1%		-6.7%$5.15B$3.51MN/A460
ACAD
ACADIA Pharmaceuticals
4.55 of 5 stars		$28.92
+1.6%		$33.44
+15.7%		+12.8%$4.95B$1.07B13.03510
DYN
Dyne Therapeutics
3.7468 of 5 stars		$25.30
-2.2%		$34.42
+36.0%		+112.1%$4.72BN/AN/A100
CELC
Celcuity
3.6795 of 5 stars		$91.25
-2.1%		$155.18
+70.1%		+65.4%$4.45BN/AN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:GLUE) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
How a rare metal shortage sent gains up 2512 percent
In 2010, a rare earth metal called dysprosium surged 2,512 percent in two and a half years after China cut exp...
Awesomely | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel